Molecular Devices Bio-Expo Live 2024: Quality, Data, & Analytical Solutions
This content is brought to you by Molecular Devices, a Danaher Operating Company.
3D in vitro models - including human organoids - represent a paradigm shift in drug discovery due to their superior physiological relevance and their ability to more faithfully predict patient response compared to the current standard of 2D cell line models. However, working with more complex models brings a unique set of challenges which must be overcome to ensure consistency, robustness and ease of use in drug discovery assays. This presentation discusses the ways in which Molecular Devices is overcoming these hurdles using innovative technologies to enable high-throughput, robust screens using these powerful cell models.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.